- List
- By Topic
- On Map
- Search Details
Recruiting, Active, not recruiting, Enrolling by invitation Studies | Alzheimer Disease | Biogen [Lead]
Need help? See RSS Feeds
Choose a feed type:
Recruiting, Active, not recruiting, Enrolling by invitation Studies | Alzheimer Disease | Biogen [Lead] (6 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
| 1 | NCT03352557 | Active, not recruiting | Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
654 | All | 50 Years to 80 Years (Adult, Older Adult) | NCT03352557 | 251AD201 2017-002901-37 |
TANGO | May 3, 2018 | July 9, 2021 | June 30, 2024 | November 24, 2017 | September 20, 2019 |
|
||
| 2 | NCT02484547 | Active, not recruiting | 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
1605 | All | 50 Years to 85 Years (Adult, Older Adult) | NCT02484547 | 221AD302 2015-000967-15 |
EMERGE | September 30, 2015 | January 30, 2020 | April 30, 2022 | June 29, 2015 | April 24, 2019 |
|
||
| 3 | NCT02477800 | Active, not recruiting | 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
1605 | All | 50 Years to 85 Years (Adult, Older Adult) | NCT02477800 | 221AD301 2015-000966-72 |
ENGAGE | August 31, 2015 | January 30, 2020 | April 30, 2022 | June 23, 2015 | April 24, 2019 |
|
||
| 4 | NCT03056729 | Recruiting | Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
48 | All | 50 Years to 80 Years (Adult, Older Adult) | NCT03056729 | 243HV101 | February 17, 2017 | February 14, 2020 | February 14, 2020 | February 17, 2017 | September 6, 2019 |
|
|||
| 5 | NCT03639987 | Active, not recruiting | A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
500 | All | 50 Years to 85 Years (Adult, Older Adult) | NCT03639987 | 221AD205 2018-002102-31 |
EVOLVE | December 20, 2018 | July 9, 2021 | November 13, 2023 | August 21, 2018 | April 16, 2019 |
|
||
| 6 | NCT03088956 | Active, not recruiting | Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD) |
|
|
Observational |
|
Industry |
|
|
40 | All | 18 Years to 80 Years (Adult, Older Adult) | NCT03088956 | 992FD001 | FORWARD | January 29, 2018 | October 28, 2019 | October 28, 2019 | March 24, 2017 | July 1, 2019 |
|
† Study has passed its completion date and status has not been verified in more than two years.

